SI1999152T1 - Vezni äślen za gm-csf receptor - Google Patents

Vezni äślen za gm-csf receptor

Info

Publication number
SI1999152T1
SI1999152T1 SI200731100T SI200731100T SI1999152T1 SI 1999152 T1 SI1999152 T1 SI 1999152T1 SI 200731100 T SI200731100 T SI 200731100T SI 200731100 T SI200731100 T SI 200731100T SI 1999152 T1 SI1999152 T1 SI 1999152T1
Authority
SI
Slovenia
Prior art keywords
binding member
csf receptor
csf
receptor
binding
Prior art date
Application number
SI200731100T
Other languages
English (en)
Inventor
Emma Suzanne Cohen
Ralph Raymond Minter
Paula Rosamund Harrison
Matthew Alexander Sleeman
Andrew Donald Nash
Louis Jerry Fabri
Original Assignee
Medimmune Limited
Zenyth Operations Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited, Zenyth Operations Pty. Ltd. filed Critical Medimmune Limited
Publication of SI1999152T1 publication Critical patent/SI1999152T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
SI200731100T 2006-03-27 2007-03-27 Vezni äślen za gm-csf receptor SI1999152T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78656906P 2006-03-27 2006-03-27
EP07712963A EP1999152B1 (en) 2006-03-27 2007-03-27 Binding member for gm-csf receptor
PCT/GB2007/001108 WO2007110631A1 (en) 2006-03-27 2007-03-27 Binding member for gm-csf receptor

Publications (1)

Publication Number Publication Date
SI1999152T1 true SI1999152T1 (sl) 2013-02-28

Family

ID=38293698

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200731100T SI1999152T1 (sl) 2006-03-27 2007-03-27 Vezni äślen za gm-csf receptor
SI200731286T SI2423230T1 (sl) 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF
SI200731285T SI2423229T1 (sl) 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200731286T SI2423230T1 (sl) 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF
SI200731285T SI2423229T1 (sl) 2006-03-27 2007-03-27 Vezni ÄŤlen za receptor GM-CSF

Country Status (16)

Country Link
US (8) US8263075B2 (sl)
EP (3) EP2423230B1 (sl)
JP (2) JP5335662B2 (sl)
KR (2) KR101481844B1 (sl)
CN (3) CN103641916A (sl)
BR (1) BRPI0709259B1 (sl)
CA (1) CA2647449C (sl)
DK (3) DK2423230T3 (sl)
ES (3) ES2424467T3 (sl)
HK (2) HK1166988A1 (sl)
MX (2) MX2008012291A (sl)
PL (3) PL2423229T3 (sl)
PT (3) PT1999152E (sl)
RU (2) RU2495050C2 (sl)
SI (3) SI1999152T1 (sl)
WO (1) WO2007110631A1 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2424467T3 (es) * 2006-03-27 2013-10-02 Medimmune Limited Miembro de unión para el receptor GM-CSF
NZ598345A (en) 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
JP5608635B2 (ja) 2008-04-07 2014-10-15 カロバイオス ファーマシューティカルズ インコーポレイティッド 心不全処置のためのｇｍ−ｃｓｆの中和方法
SI2376121T1 (sl) * 2008-12-22 2016-07-29 The University Of Melbourne Zdravljenje osteoartritisa
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
ES2685895T3 (es) 2008-12-22 2018-10-15 The University Of Melbourne Tratamiento del dolor
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
CN102439039A (zh) * 2009-05-05 2012-05-02 莫佛塞斯公司 多发性硬化的治疗
US20120165220A1 (en) * 2009-09-03 2012-06-28 Colgan Sean P Uses of CD116 Expression Level
ES2660776T3 (es) * 2011-10-10 2018-03-26 Medimmune Limited Tratamiento para la artritis reumatoide
JP6426001B2 (ja) * 2011-11-17 2018-11-21 グリア エスピー ゼット．オー．オー． 神経膠腫を治療するための組成物および方法
EP2602264A1 (en) * 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9861688B2 (en) * 2012-12-14 2018-01-09 Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz T cell receptors with MHC independent binding to GM-CSF receptor alpha chain
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
CA2922251C (en) 2013-08-30 2023-10-17 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
CA2946230A1 (en) 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
AU2015263285A1 (en) 2014-05-19 2016-11-24 Medimmune Limited Treatment for rheumatoid arthritis
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2017270027A1 (en) 2016-05-24 2018-12-06 Medimmune Limited Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
EP3589318A1 (en) * 2017-03-01 2020-01-08 MedImmune Limited Formulations of monoclonal antibodies
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
AU2019377515A1 (en) 2018-11-09 2021-05-27 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
EA202191470A1 (ru) * 2018-11-27 2021-09-07 Стейдсон (Бейджин) Биофармасьютикалз Ко., Лтд. Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения
WO2020247521A1 (en) 2019-06-03 2020-12-10 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
US20210284744A1 (en) 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
KR20230132470A (ko) 2020-12-18 2023-09-15 키닉사 파마슈티컬스, 리미티드 단백질 조성물 및 이를 생산하는 방법 및 사용하는방법
WO2023138499A1 (zh) * 2022-01-20 2023-07-27 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5629283A (en) * 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
SG59954A1 (en) * 1989-08-11 1999-02-22 Amrad Corp Ltd Improvements in granulocyte-macrophage colony- stimulating factor receptor and derivatives thereof
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5747032A (en) * 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5611394A (en) * 1992-11-19 1994-06-08 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7282567B2 (en) * 2002-06-14 2007-10-16 Immunomedics, Inc. Monoclonal antibody hPAM4
DK1572748T3 (da) * 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
ES2424467T3 (es) * 2006-03-27 2013-10-02 Medimmune Limited Miembro de unión para el receptor GM-CSF
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
BRPI0709259A2 (pt) 2011-06-28
BRPI0709259B1 (pt) 2022-05-31
KR101481844B1 (ko) 2015-01-13
PT2423230E (pt) 2013-08-26
CN101443360B (zh) 2013-11-27
SI2423230T1 (sl) 2013-09-30
WO2007110631A1 (en) 2007-10-04
JP2013121350A (ja) 2013-06-20
KR20130140186A (ko) 2013-12-23
US20240124596A1 (en) 2024-04-18
RU2008137763A (ru) 2010-05-10
MX2008012291A (es) 2009-01-12
PL2423229T3 (pl) 2013-09-30
EP1999152A1 (en) 2008-12-10
EP2423229B1 (en) 2013-05-08
KR101451546B1 (ko) 2014-10-16
AU2007231128A1 (en) 2007-10-04
EP2423230A1 (en) 2012-02-29
US20190040145A1 (en) 2019-02-07
US20140079708A1 (en) 2014-03-20
US20190309077A1 (en) 2019-10-10
US20150376285A1 (en) 2015-12-31
JP5335662B2 (ja) 2013-11-06
MX348827B (es) 2017-06-30
JP2009533020A (ja) 2009-09-17
US9085628B2 (en) 2015-07-21
US8506960B2 (en) 2013-08-13
PL2423230T3 (pl) 2013-10-31
EP2423230B1 (en) 2013-05-08
SI2423229T1 (sl) 2013-09-30
CN103641915B (zh) 2017-04-12
HK1166988A1 (en) 2012-11-16
PT1999152E (pt) 2013-01-07
EP2423229A1 (en) 2012-02-29
RU2639546C2 (ru) 2017-12-21
CA2647449A1 (en) 2007-10-04
DK2423230T3 (da) 2013-08-05
US20210147559A1 (en) 2021-05-20
US8263075B2 (en) 2012-09-11
ES2395839T3 (es) 2013-02-15
DK1999152T3 (da) 2013-01-14
PT2423229E (pt) 2013-08-22
CN103641916A (zh) 2014-03-19
US20090130093A1 (en) 2009-05-21
PL1999152T3 (pl) 2013-05-31
HK1166989A1 (en) 2012-11-16
KR20080113262A (ko) 2008-12-29
CN103641915A (zh) 2014-03-19
CA2647449C (en) 2017-05-16
US20120141464A1 (en) 2012-06-07
RU2012157042A (ru) 2014-07-10
EP1999152B1 (en) 2012-09-19
DK2423229T3 (da) 2013-08-05
ES2424468T3 (es) 2013-10-02
ES2424467T3 (es) 2013-10-02
JP5665894B2 (ja) 2015-02-04
RU2495050C2 (ru) 2013-10-10
CN101443360A (zh) 2009-05-27

Similar Documents

Publication Publication Date Title
PL1999152T3 (pl) Element wiążący receptor GM-CSF
HK1217203A1 (zh) 白介素- 的結合成員
GB2496951C (en) Binders
IL234081B (en) Antibody binds cd3–epsilon in different species
DK200800103A (en) Integreret føringskant for vindturbineblad
IL201340A (en) Antidote 3dc - epsilon in various species
EP2122511A4 (en) REST INTERFACE FOR ENTITIES
EP2114895A4 (en) TALARAZOLMETABOLITEN
GB0614727D0 (en) Solid support
EP2160336A4 (en) CONNECTION MECHANISM
EP2068017A4 (en) SLIDING MENT
HK1138281A1 (en) Minor groove binders
EP2021397A4 (en) PROCESS FOR POTENTIAL PEGYLATION
EP2108522A4 (en) BINDER
EP2007801A4 (en) BINDER FOR C-REACTIVE PROTEIN
GB2453894B (en) Binding assembly
ZA200806237B (en) Cannibinoid receptor modulators
GB0605643D0 (en) Support member
EP2088860A4 (en) COMPOUNDS FOR BINDING TO A CHEMOKINE RECEPTOR
HK1115660A1 (en) Mechanism for setting passage-forming-plates
EP1916923A4 (en) DEVICE FOR CLASSORS
GB0612891D0 (en) Disc binder
GB0603219D0 (en) Binders
GB0623399D0 (en) Receptor
GB0623853D0 (en) Receptor